Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of letrozole (Femara) and celecoxib (Celebrex) in postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer.

Next Previous
Trial Profile

Phase II study of letrozole (Femara) and celecoxib (Celebrex) in postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 17 Dec 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
  • 17 Nov 2009 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
  • 17 Nov 2009 Actual initiation date changed from Mar 2004 to Jan 2005 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top